Diphtheria - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Diphtheria - Pipeline Review, H2 2016

Diphtheria - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Diphtheria - Pipeline Review, H2 2016
Published Nov 16, 2016
82 pages — Published Nov 16, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diphtheria Pipeline Review, H2 2016, provides an overview of the Diphtheria (Infectious Disease) pipeline landscape.

Diphtheria is a bacterial infection that affects the membranes of the throat and nose. If left untreated, diphtheria can cause severe damage to kidneys, nervous system, and heart. Symptoms include sore throat and hoarseness, swollen glands (enlarged lymph nodes) in neck, nasal discharge, fever and chills and malaise. Treatment includes antitoxins and antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diphtheria Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Diphtheria (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diphtheria (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Diphtheria and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 10, 1, 5, 1, 7 and 3 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 2 molecules, respectively.Diphtheria.

Diphtheria (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diphtheria (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Diphtheria (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diphtheria (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diphtheria (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dipht

  
Source:
Document ID
GMDHC8651IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents26
  List of Tables61
  List of Figures71
Introduction81
  Global Markets Direct Report Coverage81
Diphtheria Overview91
Therapeutics Development102
  Pipeline Products for Diphtheria Overview101
  Pipeline Products for Diphtheria Comparative Analysis111
Diphtheria Therapeutics under Development by Companies122
Diphtheria Therapeutics under Investigation by Universities/Institutes141
Diphtheria Pipeline Products Glance153
  Late Stage Products151
  Clinical Stage Products161
  Early Stage Products171
Diphtheria Products under Development by Companies182
Diphtheria Products under Investigation by Universities/Institutes201
Diphtheria Companies Involved in Therapeutics Development2116
  Beijing Minhai Biotechnology Co., Ltd211
  BioClonetics Immunotherapeutics, Inc.221
  Biological E. Limited231
  Boryung Pharmaceutical Co., Ltd.241
  Daiichi Sankyo Company, Limited251
  GlaxoSmithKline Plc261
  Green Cross Corporation271
  Indian Immunologicals Limited281
  Kaketsuken K.K.291
  LG Life Science LTD.301
  Panacea Biotec Limited311
  Prometheon Pharma, LLC321
  Sanofi Pasteur SA331
  Serum Institute of India Pvt Ltd341
  Sinovac Biotech Ltd.351
  Zydus Cadila Healthcare Limited361
Diphtheria Therapeutics Assessment378
  Assessment by Monotherapy Products371
  Assessment by Combination Products381
  Assessment by Target392
  Assessment by Route of Administration412
  Assessment by Molecule Type432
Drug Profiles4533
  (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine Drug Profile451
  (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine Drug Profile461
  (diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) vaccine Drug Profile471
  (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (7-valent) vaccine Drug Profile481
  (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + polio + tetanus) (hexavalent) vaccine Drug Profile491
  (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine Drug Profile501
  (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine Drug Profile511
  (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine Drug Profile521
  (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine Drug Profile531
  (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine Drug Profile541
  (diphtheria + pertussis (acellular) + tetanus) vaccine Drug Profile551
  (diphtheria + pertussis (acellular) + tetanus) vaccine Drug Profile561
  (diphtheria + pertussis (acellular) + tetanus) vaccine Drug Profile571
  (diphtheria + pertussis (acellular) + tetanus) vaccine Drug Profile581
  (diphtheria + pertussis (acellular) + tetanus) vaccine Drug Profile591
  (diphtheria + pertussis (acellular) + tetanus) vaccine 1 Drug Profile601
  (diphtheria + pertussis (acellular) + tetanus) vaccine 2 Drug Profile611
  (diphtheria + pertussis (whole cell) + tetanus) vaccine Drug Profile621
  (diphtheria + pertussis (whole-cell) + tetanus) vaccine Drug Profile631
  (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine Drug Profile642
  (diphtheria + tetanus) vaccine Drug Profile661
  BVN-002 Drug Profile671
  diphtheria + pertussis(acellular) + tetanus vaccine Drug Profile681
  diphtheria vaccine Drug Profile691
  Eupenta Drug Profile701
  GC-1107 Drug Profile711
  GC-3111A Drug Profile721
  KD-370 Drug Profile731
  LBVD Drug Profile741
  Monoclonal Antibody for Diphtheria Drug Profile751
  VN-0103 Drug Profile761
  VN-0105 Drug Profile771
Diphtheria Dormant Projects781
Diphtheria Discontinued Products791
Diphtheria Product Development Milestones801
  Featured News &Press Releases801
    Apr 01, 2015: LG Life Sciences Succeeds in Phase 3 International Clinical Trials for 5-in-1 Vaccine Eupenta801
    Nov 24, 2014: CanSinotech submitted CTA of Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed to CFDA801
Appendix812
  Methodology811
  Coverage811
  Secondary Research811
  Primary Research811
  Expert Panel Validation811
  Contact Us811
  Disclaimer821

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Diphtheria - Pipeline Review, H2 2016" Nov 16, 2016. Alacra Store. May 03, 2025. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Diphtheria-Pipeline-Review-H2-2016-2088-16817>
  
APA:
Global Markets Direct - Market Research. (2016). Diphtheria - Pipeline Review, H2 2016 Nov 16, 2016. New York, NY: Alacra Store. Retrieved May 03, 2025 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Diphtheria-Pipeline-Review-H2-2016-2088-16817>
  
US$ 2,000.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.